1. Evaluating haemodynamic changes: vericiguat in patients with heart failure with reduced ejection fraction
- Author
-
Hideaki Suzuki, Takumi Inoue, Yousuke Terui, Kouki Takeuchi, Kai Susukita, Marina Arai, Haruka Sato, Taijyu Satoh, Saori Yamamoto, Nobuhiro Yaoita, Shunsuke Tatebe, Hideka Hayashi, Kotaro Nochioka, Hiroyuki Takahama, and Satoshi Yasuda
- Subjects
Haemodynamics ,Heart failure ,Pulmonary artery wedge pressure ,Right heart catheterization ,Vericiguat ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Aims Vericiguat has been used to treat patients with heart failure with reduced ejection fraction (HFrEF) who demonstrated worsening heart failure despite treatment with other guideline‐directed medical therapies. The haemodynamic effects of vericiguat remain unclear. Methods and results This study enrolled 12 patients (median age, 63 [quartiles 53.5, 70] years; 16.7%(N=2) women) with symptomatic HFrEF (New York Heart Association functional class II–IV) who demonstrated worsening heart failure despite treatment with the four foundational guideline‐recommended therapies between March and December 2022, with follow‐ups completed in June 2023. A balloon‐tipped pulmonary artery thermodilution catheter was placed in the right internal jugular vein to perform right heart catheterisation (RHC) on day 1. Haemodynamic data were acquired before and after vericiguat intake (2.5 mg) on days 2 and 3. The data on days 2 and 3 were averaged. RHC was repeated on day 105 (37, 168). Oral intake of vericiguat 2.5 mg decreased mean pulmonary artery pressure (19.3 [14.3, 26.8] mmHg) and pulmonary artery wedge pressure (PAWP) (11 [7.5, 15] mmHg) before the intake to mean pulmonary artery pressure (17.5 [12.5, 24] mmHg) and PAWP (9.3 [6.8, 14] mmHg) at 30 min after (both P
- Published
- 2024
- Full Text
- View/download PDF